Clinical trial
Treatment for Completers of the Study B7A-MC-MBCM
NCT00266695 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00266695 |
|---|---|
| Title | Treatment for Completers of the Study B7A-MC-MBCM |
| Official title | Open-Label Treatment for Patients Completing Study B7A-MC-MBCM |
| Lead sponsor | Chromaderm, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | Ruboxistaurin |
| Enrollment | 203 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Dec 19, 2005 |
| Last update posted | Oct 6, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: